Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Industry**: Metabolic and liver disease - **Key Product**: Rezdiffra, the first-ever approved product for MASH (Metabolic Associated Steatotic Hepatitis) Core Points and Arguments 1. **Market Leadership**: Madrigal is positioned as a leader in the MASH space with a successful product launch, achieving over $1 billion in annualized sales after six quarters [3][4][29]. 2. **Future Growth**: The company anticipates significant growth opportunities with the upcoming F4C indication data expected in 2027, which could potentially double the market opportunity for Rezdiffra [4][30]. 3. **Patient Base**: As of Q3 2025, over 29,500 patients are on Rezdiffra therapy, with 10,000 prescribers, indicating a strong foundation for continued growth [9][10]. 4. **Market Dynamics**: The MASH market is currently under-penetrated, with only 10% of diagnosed patients being treated. The company sees potential for expansion similar to other large specialty markets [11][12]. 5. **Pipeline Development**: Madrigal is focused on building a robust pipeline in MASH, including new mechanisms of action and combination therapies to enhance treatment efficacy [17][18][20]. Important Developments 1. **Combination Therapies**: The company is exploring combination therapies with new assets like a DGAT2 inhibitor and an oral GLP-1 molecule, which are expected to enhance the efficacy of Rezdiffra [20][25]. 2. **Clinical Trials**: Ongoing and upcoming trials include the Maestro Outcomes trial for F4C and the Maestro NASH study for F2, F3, with data expected in 2027 and 2028 respectively [17][18]. 3. **Market Access**: Madrigal has secured first-line access with no step-edit requirements, which is crucial for maintaining strong market presence against competitors [10][49]. Financial Outlook 1. **Sales Growth**: The company expects robust net revenue growth in 2026 despite anticipated changes in gross-to-net dynamics due to commercial contracting [49][50]. 2. **Profitability Timeline**: While profitability is not the immediate focus, the company is confident in achieving it as top-line growth outpaces spending [45][46]. Additional Insights 1. **Global Expansion**: Madrigal has launched in Germany and is exploring opportunities in other countries, particularly in the Middle East, but does not expect significant contributions from international sales in 2026 [55][56]. 2. **Competitive Landscape**: The company acknowledges the presence of competitors but believes that the unique profile of Rezdiffra and its established market access will allow it to thrive [10][53]. Conclusion Madrigal Pharmaceuticals is strategically positioned to lead the MASH market with its innovative product Rezdiffra and a growing pipeline. The company is focused on maximizing its market potential through combination therapies and expanding its patient base while maintaining a strong financial outlook for the coming years [28][30].

This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Forward-looking statements include all statements that are not h ...

Core Insights - Madrigal Pharmaceuticals has acquired exclusive global rights to ervogastat from Pfizer, enhancing its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) [1][6] - Ervogastat is a mid-stage, oral DGAT-2 inhibitor that reduces liver triglyceride levels and inflammation [1][5] - Madrigal's shares have increased by 69.3% over the past year, significantly outperforming the industry growth of 4.6% [1] Company Developments - The acquisition of ervogastat aims to develop combination therapies with Madrigal's approved therapy, Rezdiffra, to improve clinical outcomes and commercial potential for MASH treatment [3][6] - Rezdiffra is already approved in the U.S. for adult patients with noncirrhotic MASH with moderate-to-advanced liver fibrosis [4][7] Clinical Efficacy - In a phase II study, ervogastat showed significant efficacy, with 72% of patients achieving a 30% reduction in liver fat and 61% achieving a 50% reduction [5][6] - The treatment was well tolerated, and improvements in liver enzymes and stiffness were observed [5] Future Plans - Madrigal plans to conduct a drug-to-drug interaction study with Rezdiffra and consult the FDA for a phase II combination study [7][8] - The combination of ervogastat and Rezdiffra is expected to provide greater benefits due to their distinct mechanisms [8] Financial Aspects - Madrigal will make a $50 million upfront payment to Pfizer, with additional milestone and royalty payments contingent on successful development and commercialization of ervogastat [9]

Core Viewpoint - Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, enhancing its position in the development of therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][4]. Company Developments - The agreement allows Madrigal to develop, manufacture, and commercialize ervogastat, along with rights to two additional early-stage MASH pipeline assets. Pfizer received an upfront payment of $50 million, with potential additional payments and royalties based on net sales [4]. - Madrigal plans to present further details at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [2][5]. Product Information - Ervogastat is a liver-directed oral DGAT-2 inhibitor that lowers hepatic triglycerides and reduces liver inflammation. In a Phase 2 study, 72% of patients achieved at least a 30% reduction in liver fat, and 61% achieved at least a 50% reduction [3][4]. - The combination of ervogastat with Madrigal's existing product, Rezdiffra, is expected to provide additive therapeutic benefits due to their complementary mechanisms of action [3][5]. Industry Context - MASH is a serious liver disease that can lead to severe complications, including cirrhosis and liver cancer. It is the leading cause of liver transplantation in women in the U.S. and is increasingly recognized as a significant health issue [6][7]. - As awareness of MASH increases, the number of diagnosed patients with moderate to advanced fibrosis is expected to grow, highlighting the need for effective treatment options [8].

Core Insights - The article highlights the services offered by Biotech Analysis Central, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Company Overview - Biotech Analysis Central is a platform that includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports aimed at helping healthcare investors make informed decisions [2]. Group 2: Subscription Details - The service is available for $49 per month, with a promotional offer of a 33.50% discount for annual subscriptions, bringing the yearly cost to $399 [1].

Core Viewpoint - Madrigal Pharmaceuticals, Inc. will participate in the J.P. Morgan Annual Healthcare Conference on January 12, 2026, at 1:30 PM PST, with a live broadcast available for investors [1] Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [2] - The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist that targets key underlying causes of MASH [2] - Rezdiffra is the first and only medication approved by both the FDA and the European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [2] - An ongoing Phase 3 outcomes trial is assessing Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [2]

Core Viewpoint - Summit Therapeutics and Madrigal Pharmaceuticals have shown significant stock price increases over the past three years, with Summit rising 2,280% and Madrigal gaining 631%, indicating strong clinical and regulatory advancements in the biotech sector [1][2]. Group 1: Summit Therapeutics - Summit Therapeutics is developing ivonescimab, a bispecific antibody that has shown greater efficacy than Keytruda in a phase 3 study for non-small cell lung cancer, currently undergoing further studies in the U.S. [4][5]. - The market potential for ivonescimab is substantial, with analysts projecting worldwide sales of $4.4 billion by 2030 and peak sales of $53 billion, given its potential advantages over Keytruda, which generated $29.5 billion in revenue last year [7][8]. - The company’s market cap is currently $14 billion, and it has plans to target additional indications, with patent exclusivity for ivonescimab lasting until 2039, providing a long window for revenue generation [6][8][9]. Group 2: Madrigal Pharmaceuticals - Madrigal Pharmaceuticals received FDA approval for Rezdiffra, the first medication for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet medical need linked to obesity [10]. - Rezdiffra generated $287.3 million in revenue in the third quarter, reflecting a 35% quarter-over-quarter increase and a 362% rise year-over-year, with 29,500 patients currently on the medication [11][12]. - The company is expanding its market reach and seeking label expansions for Rezdiffra, with patent protection lasting until 2045 in the U.S., indicating strong future growth potential despite competition [14][15][16].

Core Insights - Galmed Pharmaceuticals has been granted a new Use Patent for its lead compound, Aramchol, covering its combination therapy with Rezdiffra for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis in South Korea [2][3] - The new patent extends Aramchol's patent protection globally until July 2042, reinforcing its position in the NASH/MASH combination therapy market [3] - The patent grant is timely as the industry is increasingly focusing on combination therapies to effectively address NASH/MASH, which has shown limited efficacy with monotherapies [4] Company Overview - Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in liver, cardiometabolic diseases, and GI oncological therapeutics, with a primary focus on developing Aramchol for liver diseases [5] - The company is actively pursuing opportunities to expand its product pipeline, particularly targeting cardiometabolic indications and innovative drug candidates [5]

Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Product**: Rezdiffra, a treatment for Metabolic Associated Steatotic Hepatitis (MASH) Key Points Financial Performance - Achieved a **$1 billion run rate** with **$287.3 million in sales** in the last quarter, indicating strong market uptake [2][20] - Over **10,000 prescribers** and **29,500 patients** on the drug, with a penetration rate of just under **10%** [2][20] - Projected revenue for **2026** is **$1.45 billion**, representing a **50% year-over-year growth** [26] Market Access and Payer Contracts - Secured favorable **payer contracting** for **2026**, ensuring first-line access with no step-throughs and improved utilization management criteria [3][20] - Gross-to-net discount expected to be in the **20%-30% range for 2025**, increasing to the **high 30% range for 2026** [21][22] Clinical Data and Product Efficacy - New data presented at the **AASLD conference** showed that discontinuation of Rezdiffra leads to a quick return of symptoms, emphasizing the need for chronic therapy [4][5] - Efficacy data from the **F4C population** showed a **decrease in liver stiffness of over 7 kPa**, providing confidence for the upcoming **MAESTRO-NASH outcomes study** in 2027 [6][8] Expansion into Endocrinology - Plans to expand focus from specialty GI and hepatologists to include **endocrinologists**, with a dedicated effort towards this specialty [10][12] - Approximately **2,000 high-target endocrinologists** have shown interest in prescribing Rezdiffra, indicating a potential market opportunity [12][13] Research and Development - Continued investment in **R&D** and **SG&A** to support the launch and pipeline development, with an increase in expenses expected [27] - The company is exploring **business development opportunities** to maintain leadership in the MASH space, including a recent deal for an oral GLP-1 asset [33][34] Future Outlook - The company believes it is at the beginning of a long growth trajectory, with significant unmet needs in the MASH market [41][42] - The potential for **multiple products** in the MASH category, with a strong pipeline and patent protection extending to **2045** [41][42] Additional Insights - The company has achieved **80% commercial coverage** within six months of launch, indicating strong market access [31] - There is a focus on maintaining excellent access for patients while navigating the complexities of payer contracts [20][21] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Madrigal Pharmaceuticals' strong market position and future growth potential in the MASH treatment landscape.

Summary of Madrigal Pharmaceuticals FY Conference Call Company Overview - **Company**: Madrigal Pharmaceuticals (NasdaqGS:MDGL) - **Product**: Rezdiffra, targeting MASH (Metabolic Associated Steatotic Liver Disease) - **Current Status**: Completed sixth quarter of product launch, achieving over $1 billion annualized run rate with over 10,000 prescribers [3][4] Key Points and Arguments Launch and Market Penetration - **Market Penetration**: Currently less than 10% penetration into a target population of 315,000 diagnosed patients [4][6] - **Sales Force Expansion**: Plans to expand sales force to include endocrinologists, responding to inbound interest from this group [7][8] - **Comparison to Other Launches**: Metrics indicate that Madrigal's launch is among the best in the last decade [5][9] Financial Metrics - **Gross to Net Discount**: Expected to rise from low 20% to high 30% as contracting gains traction; this is a normal progression for specialty products [17][20] - **Persistence Rate**: Current persistence rate observed at 90%, but conservative modeling suggests 60%-70% should be maintained for projections [11][14] Competitive Landscape - **Competitor Impact**: Despite competition from Wegovy, Madrigal expects steady patient addition due to the unique positioning of Rezdiffra [10][30] - **Pricing Pressure**: Concerns about potential pricing pressure from Semaglutide's approval for MASH, but management believes Rezdiffra's pricing will remain competitive [28][30] International Expansion - **Ex-US Launch**: Currently launched in Germany with plans for disciplined country-by-country expansion; pricing strategy includes parity with U.S. government pricing [31][32][33] Intellectual Property - **Patent Strategy**: Recently secured a dosing patent extending to 2045; decisions on extending other patents expected in 2026 [34][36] Profitability Outlook - **Focus on Growth**: Current focus is on driving sales and expanding the pipeline rather than immediate profitability; profitability may be achieved in the near term but is not the primary goal [43][46] Future Directions - **Pipeline Development**: Plans to build a franchise around Rezdiffra and explore additional mechanisms of action for future products [47] Additional Important Information - **Contracting History**: Initial six quarters had no contracting, which is unusual; now entering a more standard contracting phase [19][20] - **Market Dynamics**: The company is navigating a complex market environment with ongoing adjustments to pricing and access strategies [31][32] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Madrigal Pharmaceuticals' current status, market strategies, and future outlook.